Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Neurology|July 1, 1995
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2005
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon betaD R Smith, B Weinstock-Guttman, J A Cohen, et al.
The Journal of Nutritional Biochemistry|May 5, 2016
The delta 6 desaturase knock out mouse reveals that immunomodulatory effects of essential n-6 and n-3 polyunsaturated fatty acids are both independent of and dependent upon conversionJennifer M Monk, Danyelle M Liddle, Daniel J A Cohen, et al.
Molecular Pharmaceutics|December 5, 2006
Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylationM E Hayes, D C Drummond, K Hong, et al.
Archives of Neurology|June 1, 1997
Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosisP W Nance, W A Sheremata, S G Lynch, et al.
European Journal of Neurology|March 30, 2020
Cognitive processing speed in multiple sclerosis clinical practice: association with patient-reported outcomes, employment and magnetic resonance imaging metricsG Macaron, L E Baldassari, K Nakamura, et al.
Neurology|September 11, 2002
Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen, G R Cutter, J S Fischer, et al.
Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Archives of Neurology|June 19, 2001
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialJ A Cohen, G R Cutter, J S Fischer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2009
Assessing disability progression with the Multiple Sclerosis Functional CompositeR A Rudick, C H Polman, J A Cohen, et al.
Pageof 21